Retest positive for SARS‐CoV‐2 RNA of “recovered” patients with COVID‐19: Persistence, sampling issues, or re‐infection?

DOI Web Site Web Site Web Site 被引用文献1件
  • Hanyujie Kang
    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao‐Yang Hospital Capital Medical University Beijing China
  • Yishan Wang
    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao‐Yang Hospital Capital Medical University Beijing China
  • Zhaohui Tong
    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao‐Yang Hospital Capital Medical University Beijing China
  • Xuefeng Liu
    Departments of Pathology and Oncology, Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington, District of Columbia

説明

<jats:title>Abstract</jats:title><jats:p>“Retest Positive” for severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2) from “recovered” coronavirus disease‐19 (COVID‐19) has been reported and raised several important questions for this novel coronavirus and COVID‐19 disease. In this commentary, we discussed several questions: (a) Can SARS‐CoV‐2 re‐infect the individuals who recovered from COVID‐19? This question is also associated with other questions: whether or not SARS‐CoV‐2 infection induces protective reaction or neutralized antibody? Will SARS‐CoV‐2 vaccines work? (b) Why could some recovered patients with COVID‐19 be re‐tested positive for SARS‐CoV‐2 RNA? (c) Are some recovered pwith atients COVID‐19 with re‐testing positive for SARS‐CoV‐2 RNA infectious? and (d) How should the COVID‐19 patients with retest positive for SARS‐CoV‐2 be managed?</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ